Effect of tamoxifen on serum cholesterol and lipoproteins during chemohormonal therapy

Dnistrian, Ann M.; Schwartz, Morton K.; Greenberg, E.; Smith, C A; Schwartz, D

doi:10.1016/0009-8981(93)90061-8

Cited by 41 publications

(11 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serum HDL, LDL and total cholesterol levels were comparable between the two groups, in spite of what was shown by previous investigations [13,14]. Higher levels of serum triglycerides and free fatty acids might be a direct consequence of the conversion from white to beige adipocytes, because as known from literature lipid droplets of brown and beige adipocytes are smaller and scattered throughout.…”

Section: Discussioncontrasting

confidence: 81%

Tamoxifen affects glucose and lipid metabolism parameters, causes browning of subcutaneous adipose tissue and transient body composition changes in C57BL/6NTac mice

Hesselbarth

Pettinelli

Gericke

et al. 2015

Biochemical and Biophysical Research Communications

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 81%

Tamoxifen affects glucose and lipid metabolism parameters, causes browning of subcutaneous adipose tissue and transient body composition changes in C57BL/6NTac mice

Hesselbarth

Pettinelli

Gericke

et al. 2015

Biochemical and Biophysical Research Communications

View full text Add to dashboard Cite

“…However, derangement imbalances in serum lipoprotein metabolism, i.e. decreases in the concentration of total and low-density lipoprotein cholesterol and increases in the concentration of TGs and high-density lipoprotein cholesterol, have been reported previously (8,11,12,20). We studied one case of marked hypertriglyceridemia induced by TAM (Hozumi, Y., M. Kawano, T. Saito, M. Miyata; unpublished data).…”

Section: Discussionmentioning

confidence: 99%

Effect of Tamoxifen on Serum Lipid Metabolism

Hozumi¹,

Kawano²,

Saito³

et al. 1998

The Journal of Clinical Endocrinology & Metabolism

View full text Add to dashboard Cite

The effect of tamoxifen, an antiestrogenic agent, on lipid metabolism was studied in postmenopausal patients with breast cancer who received the drug for postoperative adjuvant treatment following mastectomy. To measure total cholesterol and triglyceride concentrations, fasting blood samples were collected before and 2 months after the initiation of tamoxifen therapy from 16 patients who satisfied the study criteria. All patients were normolipidemic before tamoxifen was administered. Control samples were obtained from hypertriglyceridemia patients who were free from breast cancer. Marked hypertriglyceridemia was observed in 3 of 16 patients after tamoxifen treatment. The activity of lipoprotein lipase and hepatic triglyceride lipase, the key enzymes of triglyceride metabolism, decreased significantly in all of 16 patients as a result of tamoxifen treatment (P ϭ 0.008 and P ϭ 0.007, respectively). However, the mean mass of lipoprotein lipase significantly increased (P ϭ 0.011) after tamoxifen treatment. We therefore conclude that tamoxifen might increase inactive lipoprotein lipase. Because marked hyperlipidemia is a potent risk factor for life-threatening acute pancreatitis and arteriosclerosis, plasma lipid levels should be tested periodically during tamoxifen treatment, even if the patients are normolipidemic during the pretreatment stage. (J Clin Endocrinol Metab 83: [1633][1634][1635] 1998) T AMOXIFEN (TAM), a nonsteroidal estrogen antagonist, has been widely used since the 1970s in adjuvant hormonal treatment of primary breast cancer (1). TAM interferes with the estrogen-dependent proliferation of breast cancer cells and improves the postoperative prognosis of patients with breast cancer of postmenopausal onset (2, 3). Although the optimal duration of adjuvant treatment has not yet been determined, the currently available limited data suggest that the longer the treatment, the more beneficial, and that administration of TAM for 5 yr significantly reduces the recurrence of carcinoma (4 -7).The side effects of TAM are generally mild, including those affecting lipoprotein metabolism. Although several studies described small changes in plasma lipoprotein concentrations, most of the changes reduce the risk of cardiovascular disease (8 -14). However, a case of marked TAM-induced hypertriglyceridemia also was reported by Brun et al. (15). We recently found a severely elevated triglyceride (TG) level exceeding 2000 mg/dL, which may induce lethal pancreatitis in these patient (Hozumi Y., M. Kawano, T. Saito, M. Miyata; unpublished data). This patient was not included in this study. Therefore, the effects of TAM on lipid metabolism should not be ignored.To study the mechanisms of TAM-induced hyperlipidemia, we prospectively studied the lipolytic enzymes in postheparin plasma (PHP) before and 8 weeks after TAM administration; TAM has been shown to require approximately 4 weeks to reach steady state (16). We also tested the susceptibility of serum TG from patients treated with TAM to the hydrolytic activity ...

show abstract

“…15 When premenopausal and postmenopausal patients with advanced breast cancer received chemohormonal therapy, the levels of total cholesterol and low-density lipoprotein cholesterol were significantly lowered. 16 In this study, total serum cholesterol levels were lowered in postmenopausal women receiving chemohormonal therapy, although tamoxifen did not influence total serum cholesterol levels in premeno1mot() pausal women treated with tamoxifen or chemohormonal therapy; this is why these premenopausal women had low baseline levels of total serum cholesterol.…”

Section: Discussionmentioning

confidence: 65%

Effect of tamoxifen on serum cholesterol in Japanese women with breast cancer

Imoto

1998

Int J Clin Oncol

View full text Add to dashboard Cite

Background:To investigate whether tamoxifen therapy has a favorable effect on plasma lipids, serum cholesterol levels were measured in 228 Japanese women with breast cancer (116 premenopausal women and 112 postmenopausal women).Methods: These women were treated with tamoxifen or tamoxifen + chemotherapy (tamoxifen-treated group) or were given no therapy or chemotherapy alone (control group). Results: There was no difference between cholesterol levels before treatment and after a 2-year follow-up period in these groups, except for the postmenopausal tamoxifen-treated group. In this particular group, the mean levels of serum cholesterol after 1 and 2 years of follow-up (197 and 188 mg/dL, respectively) were 8% and 12% lower than those before treatment (215 mg/dL, P < 0.0001 ). In addition, the mean level of serum cholesterol after a 2-year follow-up period was significantly higher in the postmenopausal tamoxifen-treated group than in the postmenopausal control group (218 and 188 mg/dL, respectively, P = 0.0066). Conclusions:In multiple regression models that included age, body mass index, and chemohormonal therapy, only tamoxifen treatment appeared to predict the change between cholesterol levels before treatment and after 2-year follow-up in postmenopausal women. These results suggest that tamoxifen has the potential benefit of reducing the serum cholesterol level, which may be closely related to cardiovascular risk, in Japanese postmenopausal women.Int J Clin Oncol 1998;3:88-92

show abstract

Effect of tamoxifen on serum cholesterol and lipoproteins during chemohormonal therapy

Cited by 41 publications

References 24 publications

Tamoxifen affects glucose and lipid metabolism parameters, causes browning of subcutaneous adipose tissue and transient body composition changes in C57BL/6NTac mice

Tamoxifen affects glucose and lipid metabolism parameters, causes browning of subcutaneous adipose tissue and transient body composition changes in C57BL/6NTac mice

Effect of Tamoxifen on Serum Lipid Metabolism

Effect of tamoxifen on serum cholesterol in Japanese women with breast cancer

Contact Info

Product

Resources

About